Revised Guidelines for smoking cessation in New Zealand, 2021.


Journal

The New Zealand medical journal
ISSN: 1175-8716
Titre abrégé: N Z Med J
Pays: New Zealand
ID NLM: 0401067

Informations de publication

Date de publication:
15 07 2022
Historique:
entrez: 14 7 2022
pubmed: 15 7 2022
medline: 19 7 2022
Statut: epublish

Résumé

To summarise the literature underpinning key recommendations made in the 2021 revision of the Ministry of Health's New Zealand Guidelines for Helping People to Stop Smoking. A comprehensive literature review of smoking cessation interventions was undertaken in July 2021. Recommendations were formulated from the findings of the literature review and expert advice. Healthcare professionals should ask and briefly advise all people who smoke to stop smoking, regardless of whether they say they are ready to stop smoking or not. They should offer smoking cessation support, which includes both behavioural and pharmacological (e.g., nicotine replacement therapy, nortriptyline, bupropion or varenicline) interventions. The Guidelines also include advice around the use of vaping in smoking cessation. Recommendations are also formulated for priority populations of smokers: Māori, Pacific, pregnant women, and people with mental illness and other addictions. The guidelines will assist healthcare professionals in providing evidence-based smoking cessation support to people who smoke. To be effective and equitable, the ABC model requires organisational commitment, integration into routine practice, and increased attention to the upstream determinants of smoking and quitting.

Identifiants

pubmed: 35834834

Substances chimiques

Varenicline W6HS99O8ZO

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-64

Déclaration de conflit d'intérêts

Nil.

Auteurs

Jessica McCormack (J)

National Institute for Health Innovation, School of Population Health, The University of Auckland, New Zealand.

Natalie Walker (N)

National Institute for Health Innovation, School of Population Health, The University of Auckland, New Zealand.

Hayden McRobbie (H)

National Drug and Alcohol Research Centre, University of New South Wales, Australia.

Karen Wright (K)

Te Kupenga Hauora Māori, The University of Auckland, New Zealand.

Vili Nosa (V)

Pacific Health, School of Population Health, The University of Auckland, New Zealand.

Basil Fernandes (B)

Counties Manukau Health Living Smokefree Service.

Chris Bullen (C)

National Institute for Health Innovation, School of Population Health, The University of Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH